PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31354046-1	2019	We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer.	cit	98-101	CD274 molecule	Homo sapiens	18-23	
31354046-6	2019	PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.	cit	30-33	CD274 molecule	Homo sapiens	0-5	
30419350-5	2019	Programmed cell death ligand-1 (PD-L1), which is a validated biomarker in non-small cell lung cancer (NSCLC), is often also used to select patients for CIT in the context of gastroesophageal cancer, although this marker has not been validated for this purpose.	cit	152-155	CD274 molecule	Homo sapiens	0-30	
30419350-5	2019	Programmed cell death ligand-1 (PD-L1), which is a validated biomarker in non-small cell lung cancer (NSCLC), is often also used to select patients for CIT in the context of gastroesophageal cancer, although this marker has not been validated for this purpose.	cit	152-155	CD274 molecule	Homo sapiens	32-37	
30419350-7	2019	This review discusses the value of PD-L1 in selecting patients for CIT in esophageal and gastric cancer.	cit	67-70	CD274 molecule	Homo sapiens	35-40